FY2017 EPS Estimates for Urogen Pharma Decreased by Oppenheimer Holdings (URGN)

Urogen Pharma (NASDAQ:URGN) – Equities research analysts at Oppenheimer Holdings reduced their FY2017 earnings estimates for shares of Urogen Pharma in a research report issued on Tuesday. Oppenheimer Holdings analyst D. Archila now forecasts that the company will earn ($2.05) per share for the year, down from their prior forecast of ($1.90). Oppenheimer Holdings currently has a “Outperform” rating and a $51.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Urogen Pharma’s Q4 2017 earnings at ($0.67) EPS, FY2018 earnings at ($2.60) EPS, FY2019 earnings at ($1.79) EPS, FY2020 earnings at $0.99 EPS and FY2021 earnings at $3.82 EPS.

ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for Urogen Pharma Decreased by Oppenheimer Holdings (URGN)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/11/17/fy2017-eps-estimates-for-urogen-pharma-decreased-by-oppenheimer-holdings-urgn.html.

A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Urogen Pharma from a “hold” rating to a “sell” rating in a report on Thursday, September 14th. Jefferies Group LLC raised their price target on shares of Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Monday, October 9th. Raymond James Financial, Inc. cut shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday. CIBC restated an “outperform” rating and issued a $51.00 price target (up from $32.00) on shares of Urogen Pharma in a report on Wednesday. Finally, Cowen and Company restated a “buy” rating on shares of Urogen Pharma in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $36.80.

Urogen Pharma (NASDAQ:URGN) traded up $0.75 on Friday, hitting $41.00. 176,311 shares of the stock traded hands, compared to its average volume of 62,480. Urogen Pharma has a 52 week low of $13.01 and a 52 week high of $44.63.

A number of large investors have recently bought and sold shares of URGN. FMR LLC acquired a new stake in Urogen Pharma in the second quarter worth $13,892,000. Menora Mivtachim Holdings LTD. grew its holdings in shares of Urogen Pharma by 341.4% during the third quarter. Menora Mivtachim Holdings LTD. now owns 569,589 shares of the company’s stock valued at $17,953,000 after buying an additional 440,534 shares during the last quarter. Hillhouse Capital Management Ltd. acquired a new position in shares of Urogen Pharma during the second quarter valued at about $6,363,000. Jennison Associates LLC acquired a new position in shares of Urogen Pharma during the second quarter valued at about $3,168,000. Finally, Wildcat Capital Management LLC acquired a new position in shares of Urogen Pharma during the second quarter valued at about $2,439,000. Institutional investors and hedge funds own 40.55% of the company’s stock.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

What are top analysts saying about Urogen Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Urogen Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit